Related Experiment Video

Updated: Mar 22, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.4K

Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction

Paolo G Camici1, Steffen Gloekler2, Bernard I Levy3

  • 1Vita Salute University, San Raffaele Hospital, Milan, Italy.

International Journal of Cardiology
|April 23, 2016
PubMed

Insights

Ivabradine effectively treats angina by reducing heart rate and improving coronary blood flow, offering benefits beyond traditional beta-blockers for coronary artery disease patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart rate significantly impacts myocardial ischemia by increasing oxygen demand and reducing diastolic time.
  • Ivabradine selectively inhibits the If current in sinoatrial node cells to lower heart rate.

Purpose of the Study:

  • To compare the effects of ivabradine and beta-blockers on myocardial ischemia and coronary blood flow.
  • To elucidate the unique mechanisms of ivabradine in managing coronary artery disease.

Main Methods:

  • Pharmacological inhibition of the If current by ivabradine.
  • Comparative analysis of hemodynamic and coronary blood flow effects versus beta-blockers.
  • Assessment of myocardial oxygen supply and demand balance.

Main Results:

  • Ivabradine reduces heart rate without negative inotropic/lusitropic effects, unlike beta-blockers.
  • Ivabradine enhances diastolic duration and coronary blood flow, improving coronary flow reserve and collateral perfusion.
  • Ivabradine attenuates ischemia, potentially via reduced reactive oxygen species, and maintains coronary dilation during exercise.

Conclusions:

  • Ivabradine offers distinct advantages over beta-blockers in treating angina and myocardial ischemia.
  • Its ability to improve coronary blood flow and exert pleiotropic effects makes it a valuable therapeutic option.
  • Ivabradine is an effective anti-anginal and anti-ischemic agent for patients with coronary artery disease.

Keywords:
Angina pectorisAnti-anginal drugBeta-blockerCoronary artery diseaseCoronary blood flowCoronary collateral circulation

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.8K

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.6K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K